Critical Therapeutics to Webcast New York Meeting with Institutional Investors and Analysts.LEXINGTON, Mass. -- Critical Therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. , Inc. (Nasdaq: CRTX) will host a meeting in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. with members of the financial community on Tuesday, September 20, 2005. A live webcast of the meeting will begin at 12:30 p.m. ET. Members of Critical Therapeutics' senior management team will discuss the Company's strategy and operations, including the planned launch - pending regulatory approval - of ZYFLO Zileuton (Zyflo) A medication that interferes with the biosynthetic pathway that produces leukotrienes; used to help prevent asthma attacks. Mentioned in: Leukotriene Inhibitors Zyflo® Zileuton, see there (R) Filmtab(R) (zileuton zileuton /zi·leu·ton/ (zi-loo´ton) an inhibitor of leukotriene formation, used as an antiasthmatic. Zileuton (Zyflo) tablets) for asthma. Management also will review the status of the Company's drug discovery and development pipeline. Presenters include: --Paul Rubin, M.D., President and Chief Executive Officer --Frank Thomas, Senior Vice President and Chief Financial Officer --Rick Finnegan, Senior Vice President of Sales and Marketing Who: Critical Therapeutics, Inc. What: New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of Analyst Meeting When: 12:30 p.m. ET Tuesday, September 20, 2005 - live webcast begins How: A live audio webcast of the meeting will be available by logging on to the "Investors" section of the Company's website, www.crtx.com, and clicking on the "Live Webcast" icon on the Investors Overview page. A replay of the webcast will be available for 60 days following the live presentation. About Critical Therapeutics Critical Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of products for respiratory, inflammatory and critical care diseases. The Company plans to launch its inaugural product, the asthma medication ZYFLO(R) Filmtab(R) (zileuton tablets), into the U.S. market in the fourth quarter of 2005, subject to regulatory approval. Critical Therapeutics also is developing treatments directed toward the severe inflammatory response in acute diseases and conditions that lead to admission to the emergency room or intensive care unit, and acute exacerbations of other chronic diseases that frequently lead to hospitalization hospitalization /hos·pi·tal·iza·tion/ (hos?pi-t'l-i-za´shun) 1. the placing of a patient in a hospital for treatment. 2. the term of confinement in a hospital. . For more information, please visit www.crtx.com. ZYFLO(R) is a registered trademark of Critical Therapeutics, Inc. Filmtab(R) is a registered trademark of the Abbott Group of Companies. Forward-Looking Statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. Any statements in this press release or the webcast about future expectations, plans and prospects for the Company, including, without limitation, statements regarding the timing and success of regulatory approvals and product launches; the progress and timing of our drug discovery and development programs and related trials; the efficacy of our drug candidates; and our strategy, future operations, financial position and future revenues, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Without limiting the foregoing, the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "project," "should," "will," "would" and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks and uncertainties relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc : conducting clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. and clinical trials with respect to our products under development and whether such results will be indicative of results obtained in later clinical trials; the timing and success of submission, acceptance and approval of our regulatory filings, including, without limitation, the supplemental NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any for ZYFLO; our heavy dependence on the commercial success of ZYFLO and the controlled-release formulation formulation /for·mu·la·tion/ (for?mu-la´shun) the act or product of formulating. American Law Institute Formulation of zileuton; our ability to obtain the substantial additional funding required to conduct our research, development and commercialization activities; our dependence on our strategic collaboration with MedImmune, Inc.; and our ability to obtain, maintain and enforce patent and other intellectual property protection for drug candidates and our discoveries. These and other risks are described in greater detail in the "Factors That May Affect Future Results" section of our most recent Quarterly Report on Form 10-Q Form 10-Q See 10-Q. and other filings that we make with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release and the webcast represent the Company's views as of the date of this press release and the webcast. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release or the webcast as applicable. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion